Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

Recruiting now

Conditions studied: Laboratory-confirmed Bloodstream Infection, Central Line-associated Bloodstream Infections, Mucosal Barrier Injury

In brief

Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.

Key facts

Study ID

NCT02271243

Run by

Boston Children's Hospital

People needed

60

Starts

2014-11-01

Expected to finish

2027-12-01

Last updated by the study team

2026-05-15

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized at Boston Children's Hospital
• Central venous catheter of any type including peripherally inserted central catheters (PICC) in any location.
• Laboratory-confirmed bloodstream infection (LCBI) diagnosed by a clinical blood culture growing certain Gram-negative rods

You may not qualify if…

• Patients with CDC-defined secondary bloodstream infections

Where it is running

• Boston Children's Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.